- Home
- / Karyopharm Therapeutics
Karyopharm Therapeutics
Stock Price
$1.4
2023-09-01
Market Capitalization
$156.7 M
2023-08-30
Revenue
$157.1 M
FY, 2022
Karyopharm Therapeutics Summary
Company Summary
- Overview
- Karyopharm Therapeutics is a pharmaceutical company that discovers and develops drugs for the treatment of cancer and other major diseases. It provides small-molecule drugs that will modulate the activity of inflammation and diseases related to cell proliferation.
- Type
- Public
- Status
- Active
- Founded
- 2008
- HQ
- Newton, MA, US | view all locations
- Website
- https://www.karyopharm.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Brian Austad, Senior Vice President, Pharmaceutical Sciences
Sharon Shacham, Founder and Scientific Advisory Board Member
James Accumanno, Chief Compliance Officer
Operating MetricsView all
Patents Issued
10
FY, 2015
LocationsView all
3 locations detected
Newton, MA HQ
United States
85 Wells Ave
Munich, Bayern
Germany
9 Franziska-Bilek-Weg
Giv'atayim, Tel Aviv District
Israel
Ariel Sharon St 4
Karyopharm Therapeutics Financials
Summary Financials
- Revenue (Q2, 2023)
- $37.6M
- Net income (Q2, 2023)
- ($32.6M)
- Cash (Q2, 2023)
- $80.9M
- EBIT (Q2, 2023)
- ($29.6M)
- Enterprise value
- $83.4M